Churchill Capital XI Stock Price, News & Analysis
Company Description
Churchill Capital XI (NASDAQ: CCXI) is a publicly traded pharmaceutical preparation manufacturing company in the Manufacturing sector. The company has a market capitalization of $565.8M, ranking #3,310 among all listed U.S. companies by market cap.
CCXI stock has declined 1.0% over the past year. Shares last traded at $10.16.
This page provides a comprehensive overview of CCXI stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Churchill Capital XI (CCXI) stock last traded at $10.16. Over the past 12 months, the stock has lost 1.0%. At a market capitalization of $565.8M, CCXI is classified as a small-cap stock with approximately 55.7M shares outstanding.
Latest News
Churchill Capital XI has 10 recent news articles. Of the recent coverage, 6 articles coincided with positive price movement and 4 with negative movement. Key topics include acquisition, conferences, earnings, management, clinical trial. View all CCXI news →
SEC Filings
Churchill Capital XI has filed 5 recent SEC filings, including 2 Form 3, 2 Form SCHEDULE 13G, 1 Form 8-K. The most recent filing was submitted on March 20, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all CCXI SEC filings →
Financial Highlights
Upcoming Events
Short Interest History
Days to Cover History
CCXI Company Profile & Sector Positioning
Churchill Capital XI (CCXI) operates in the Pharmaceutical Preparation Manufacturing industry within the broader Manufacturing sector and is listed on the NASDAQ.
Investors comparing CCXI often look at related companies in the same sector, including Metsera (MTSR), Adma Biologics (ADMA), Mirum Pharmaceuticals (MIRM), Protagonist Ther (PTGX), and Ascentage Pharma Group International (AAPG). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate CCXI's relative position within its industry.